Study of ALD-401 Via Intracarotid Infusion in Ischemic Stroke Subjects
Public ClinicalTrials.gov record NCT01273337. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2 Randomized, Controlled Study With a Phase 1 Safety Cohort Testing ALD-401 Derived From Autologous Bone Marrow Delivered Via Intracarotid Infusion in Subjects With Ischemic Stroke With Blinded Assessments
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study is to demonstrate the safety of the delivery of ALD-401 by intracarotid infusion and to assess efficacy of treatment in subjects who have had unilateral, predominately cortical, ischemic strokes in the middle cerebral artery (MCA). ALD-401 is made from the stroke patient's bone marrow and infused 13-19 days after the stroke.
Study identification
- NCT ID
- NCT01273337
- Recruitment status
- Not listed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 100 participants
Conditions and interventions
Eligibility (public fields only)
- Age range
- 30 Years to 83 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Mar 2011 (Type not available)
- Primary completion
- Jul 2014 (Estimated)
- Completion
- Jan 2015 (Estimated)
- Last update posted
- Jan 16, 2014
2011 – 2015
United States locations
- U.S. sites
- 9
- U.S. states
- 8
- U.S. cities
- 9
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Los Angeles Brain and Spine Institute | Los Angeles | California | 90027 | — |
| University of Miami Hospital | Miami | Florida | 33136 | — |
| Minneapolis Heart Institute | Minneapolis | Minnesota | 55407 | — |
| Duke University Medical Center | Durham | North Carolina | 27710 | — |
| Ohio Health Research Institute | Columbus | Ohio | 43214 | — |
| University of Pittsburgh Medical Center Presbyterian Hospital | Pittsburgh | Pennsylvania | 15213 | — |
| University Medical Center at Brackenridge | Austin | Texas | 78701 | — |
| The University of Texas Medical School | Houston | Texas | 77030 | — |
| Swedish Medical Center, Cherry Hill Campus | Seattle | Washington | 98122 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01273337, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jan 16, 2014 · Synced Oct 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT01273337 live on ClinicalTrials.gov.